JACKSONVILLE, Fla., December 16, 2025 — Mayo Clinic Jacksonville has come online as the third clinical site in Breathe BioMedical’s ongoing multi-center clinical study aimed at developing a non-invasive breath test for the early detection of breast cancer in females with dense breast tissue. The activation of a leading academic medical center marks a critical step in expanding clinical validation efforts for a novel diagnostic approach designed to address limitations of conventional imaging and improve early cancer detection in an underserved patient population.
Science Significance
The study’s scientific importance lies in its exploration of breath-based biomarkers as indicators of early-stage breast cancer. By analyzing volatile organic compounds (VOCs) present in exhaled breath, the research seeks to identify metabolic signatures associated with malignancy. This approach represents a shift toward non-invasive, real-time diagnostics that can complement existing screening modalities. The inclusion of Mayo Clinic Jacksonville strengthens the scientific rigor of the trial by increasing patient diversity, sample size, and data robustness, all of which are essential for validating diagnostic accuracy, sensitivity, and specificity in real-world clinical settings.
Regulatory Significance
From a regulatory perspective, the expansion to an additional Mayo Clinic site underscores the study’s adherence to Good Clinical Practice (GCP) and regulated clinical research standards. Multi-center diagnostic studies are a key requirement for demonstrating clinical validity and reproducibility, which are essential elements in future regulatory submissions. The involvement of a globally recognized institution enhances confidence in data integrity, protocol compliance, and quality oversight, supporting the pathway toward eventual regulatory review of the breath test as a clinically deployable diagnostic tool.
Business Significance
Advertisement
For Breathe BioMedical, adding Mayo Clinic Jacksonville represents a strategic milestone that enhances the credibility and commercial potential of its diagnostic platform. Early cancer detection technologies attract significant interest due to their potential to reduce treatment costs and improve outcomes. Demonstrating successful collaboration with premier healthcare institutions positions the company favorably for future partnerships, funding opportunities, and broader clinical adoption. The multi-center study design also signals scalability, a critical factor for commercialization in competitive diagnostic markets.
Patients’ Significance
Patients stand to benefit significantly from the development of a simple, non-invasive breath test, particularly women with dense breast tissue who often face reduced sensitivity with traditional mammography. Early detection remains one of the most important predictors of breast cancer survival. By enabling earlier and more accessible screening, the technology under investigation could reduce diagnostic delays, minimize anxiety associated with invasive procedures, and support more personalized clinical decision-making. The study’s focus on a high-risk subgroup highlights its potential to address unmet clinical needs.
Policy Significance
At the policy level, the study aligns with broader healthcare priorities emphasizing early detection, preventive care, and innovation in diagnostics. Dense breast tissue is a recognized challenge in breast cancer screening, and policymakers increasingly support research that improves equity and effectiveness in cancer detection. Non-invasive diagnostic tools such as breath tests could inform future screening guidelines and public health strategies, while also reducing strain on imaging resources and healthcare systems through earlier intervention.
The addition of Mayo Clinic Jacksonville as the third site in Breathe BioMedical’s clinical study highlights the growing momentum behind breath-based diagnostics as a promising frontier in cancer detection. By combining rigorous multi-center clinical research with innovative science, the program advances the goal of earlier, more accurate, and patient-friendly breast cancer screening. As the study progresses, its findings may help shape the future of non-invasive diagnostics within regulated clinical practice.
Source: Breathe BioMedical Inc. press release
